comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 08:50:58 - browse：29267

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

WSS

Will the FTC rein in IQVIA's health data empire?

Senate panel puts off hardest PBM reforms for another day

Why doctors need education on FDA device approval process

NIH director takes cautious approach to Biden drug pricing priority

eGenesis tests gene

Biotech venture capitalists face new demands from investors

knowledge

comprehensive

focus

Medical records are filled with copy

FDA clears AI tool for detecting skin cancer

Walensky prepares to leave CDC — and Congress — behind

Dewpoint Therapeutics lays off staff after losing partnerships

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Parkinson’s finding may lead to tests and, someday, treatments

Medicare details structure of new drug price negotiation program

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why patients can’t get everything they want on drug pricing

hotspot

Think you might have Covid

Think you might have Covid

In the gardens at Boston Children's Hospital, families find sanctuary

Dewpoint Therapeutics lays off staff after losing partnerships

AI generated plenty of interest at JPM but not a lot of trust

Independent physicians launch a new lobbying group

Wikipedia

hotspot

focus

focus